AGUIAR ERIC 4

What Happened

• Eric Aguiar, a director of BridgeBio Pharma, was granted equity awards on 2026-06-22: 3,990 restricted stock units (RSUs) and 5,277 derivative RSUs, each at $0.00 (total units = 9,267). These are awards (transaction code A), not purchases or sales, so no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (appears to be timely — Form 4s are due within two business days).
• Grant price: $0.00 per unit; reported total immediate value: $0 at grant (future value depends on the stock price when/if units convert to shares).
• Vesting: RSUs vest in full on June 22, 2027, conditioned on Aguiar’s continued service on the board (per footnotes).
• Each RSU represents a contingent right to receive one share of common stock upon vesting.
• Shares owned after the reported transaction are not specified in the provided excerpt.
• Filing includes Exhibit 24 (Power of Attorney).

Context

• These are time‑based equity awards (RSUs) granted under the company’s 2021 stock plan and do not indicate an open‑market purchase or sale. RSUs generally convert to actual shares only upon vesting (here, 06/22/2027) and are commonly used for director compensation rather than immediate insider trading signals.